MCG
GTBP icon

McCollum Christoferson Group’s GT Biopharma GTBP Stock Holding History

McCollum Christoferson Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-583
Closed -$5.46K – 70
2023
Q2 		$5.46K Buy
+583
New +$6.04K ﹤0.01% 71

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFS
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

McCollum Christoferson Group's GTBP Position: Q3 2023 in Review

McCollum Christoferson Group sold out of GT Biopharma (GTBP) in Q3 2023, closing a stake of 583 shares — an estimated $5.46K sold.

McCollum Christoferson Group first reported a position in GTBP in Q2 2023 and held it in 1 quarter. The position peaked at $5.46K in Q2 2023. 32 funds tracked by Wall St. Rank hold GTBP as of Q3 2023.

  • McCollum Christoferson Group reported no remaining GT Biopharma position as of Q3 2023 after selling out during the quarter.
  • McCollum Christoferson Group sold 583 GT Biopharma shares in Q3 2023, an estimated $5.46K.
  • McCollum Christoferson Group first reported a position in GT Biopharma in Q2 2023 and held it in 1 quarter.
  • McCollum Christoferson Group's GT Biopharma position peaked at $5.46K in Q2 2023.
  • 32 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2023.

Based on McCollum Christoferson Group's 13F filing for Q3 2023, filed 8 Nov 2023.